JP Morgan Chase
KZIA

JP Morgan Chase’s Kazia Therapeutics KZIA Stock Holding History

JP Morgan Chase’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,441
Closed -$12.8K – 7548
2024
Q4 		$12.8K Buy
1,441
+684
+90% +$15.8K ﹤0.01% 6345
2024
Q3 		$16.3K Buy
+757
New +$15.1K ﹤0.01% 6282
2024
Q2 		– Hold
0
– – – 7288
2024
Q1 		– Hold
0
– – – 7333
2021
Q4 		– Hold
0
– – – 6814
2021
Q3 		– Hold
0
– – – 6651
2021
Q2 		– Hold
0
– – – 6477

Other funds holding KZIA

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase's KZIA Position: Q1 2025 in Review

JP Morgan Chase sold out of Kazia Therapeutics (KZIA) in Q1 2025, closing a stake of 1,441 shares — an estimated $12.8K sold.

JP Morgan Chase first reported a position in KZIA in Q3 2024 and held it in 2 quarters. The position peaked at $16.3K in Q3 2024. 9 funds tracked by Wall St. Rank hold KZIA as of Q1 2025.

  • JP Morgan Chase reported no remaining Kazia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 1,441 Kazia Therapeutics shares in Q1 2025, an estimated $12.8K.
  • JP Morgan Chase first reported a position in Kazia Therapeutics in Q3 2024 and held it in 2 quarters.
  • JP Morgan Chase's Kazia Therapeutics position peaked at $16.3K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.